September 20, 2025

Astragaloside IV Improves Cognitive Impairment by Reducing β-Amyloid and Tau Protein Deposition in Hippocampal Tissue of db/db Mice: A PET/CT Imaging-Based Study.

View Full Paper

Ask AI

Bookmark

Authors

Discussion

This PET/CT study demonstrates that astragaloside IV reduces beta-amyloid and tau buildup in db/db mice, suggesting a pathway involving TNF-α.

Astragaloside IV improved cognitive function by decreasing beta-amyloid and tau deposits in the hippocampus of db/db mice.
Treated db/db mice showed significant reductions in fasting glucose and enhanced glucose tolerance after eight weeks of astragaloside IV treatment.
PET imaging revealed a marked reduction of beta-amyloid and tau proteins, indicating effective neuroprotection owing to astragaloside IV.
Results suggest that astragaloside IV’s effects are mediated through the TNF-α activated EGFR/NF-κB signaling pathway.

Jiang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

September 20, 2025

View Full Paper

Ask AI

Bookmark

Authors

This PET/CT study demonstrates that astragaloside IV reduces beta-amyloid and tau buildup in db/db mice, suggesting a pathway involving TNF-α.

Astragaloside IV improved cognitive function by decreasing beta-amyloid and tau deposits in the hippocampus of db/db mice.
Treated db/db mice showed significant reductions in fasting glucose and enhanced glucose tolerance after eight weeks of astragaloside IV treatment.
PET imaging revealed a marked reduction of beta-amyloid and tau proteins, indicating effective neuroprotection owing to astragaloside IV.
Results suggest that astragaloside IV’s effects are mediated through the TNF-α activated EGFR/NF-κB signaling pathway.

Jiang et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark